Tetraspanin CD9 affects HPV16 infection by modulating ADAM17 activity and the ERK signalling pathway.


Journal

Medical microbiology and immunology
ISSN: 1432-1831
Titre abrégé: Med Microbiol Immunol
Pays: Germany
ID NLM: 0314524

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 29 01 2020
accepted: 24 03 2020
pubmed: 10 5 2020
medline: 26 1 2021
entrez: 10 5 2020
Statut: ppublish

Résumé

Human papillomaviruses (HPV) are causative agents of various tumours such as cervical cancer. HPV binding to the cell surface of keratinocytes leads to virus endocytosis at tetraspanin enriched microdomains. Complex interactions of the capsid proteins with host proteins as well as ADAM17-dependent ERK1/2 signal transduction enable the entry platform assembly of the oncogenic HPV type 16. Here, we studied the importance of tetraspanin CD9, also known as TSPAN29, in HPV16 infection of different epithelial cells. We found that both overexpression and loss of the tetraspanin decreased infection rates in cells with low endogenous CD9 levels, while reduction of CD9 expression in keratinocytes that exhibit high-CD9 protein amounts, led to an increase of infection. Therefore, we concluded that low-CD9 supports infection. Moreover, we found that changes in CD9 amounts affect the shedding of the ADAM17 substrate transforming growth factor alpha (TGFα) and the downstream phosphorylation of ERK. These effects correlate with those on infection rates suggesting that a specific CD9 optimum promotes ADAM17 activity, ERK signalling and virus infection. Together, our findings implicate that CD9 regulates HPV16 infection through the modulation of ADAM17 sheddase activity.

Identifiants

pubmed: 32385608
doi: 10.1007/s00430-020-00671-5
pii: 10.1007/s00430-020-00671-5
pmc: PMC7206579
doi:

Substances chimiques

CD9 protein, human 0
TGFA protein, human 0
Tetraspanin 29 0
Transforming Growth Factor alpha 0
ADAM17 Protein EC 3.4.24.86
ADAM17 protein, human EC 3.4.24.86

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

461-471

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : FL 696/3-1
Organisme : Deutsche Forschungsgemeinschaft
ID : 125440785 -SFB877 (A4)

Références

Egawa N, Egawa K, Griffin H, Doorbar J (2015) Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 7:3863–3890. https://doi.org/10.3390/v7072802
doi: 10.3390/v7072802 pubmed: 26193301 pmcid: 4517131
Doorbar J, Quint W, Banks L et al (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55–70. https://doi.org/10.1016/j.vaccine.2012.06.083
doi: 10.1016/j.vaccine.2012.06.083 pubmed: 23199966
Hausen HZ (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350. https://doi.org/10.1038/nrc798
doi: 10.1038/nrc798 pubmed: 12044010
Hausen zur H, (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384:260–265. https://doi.org/10.1016/j.virol.2008.11.046
doi: 10.1016/j.virol.2008.11.046
Doorbar J (2005) The papillomavirus life cycle. J Clin Virol 32(Suppl 1):S7–15. https://doi.org/10.1016/j.jcv.2004.12.006
doi: 10.1016/j.jcv.2004.12.006 pubmed: 15753007
Raff AB, Woodham AW, Raff LM et al (2013) The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol 87:6062–6072. https://doi.org/10.1128/JVI.00330-13
doi: 10.1128/JVI.00330-13 pubmed: 23536685 pmcid: 3648114
Ozbun MA (2019) Extracellular events impacting human papillomavirus infections: Epithelial wounding to cell signaling involved in virus entry. Papillomavirus Res. https://doi.org/10.1016/j.pvr.2019.04.009
doi: 10.1016/j.pvr.2019.04.009 pubmed: 30981651 pmcid: 6514438
Payne E, Bowles M, Don A et al (2001) Human papillomavirus type 6b virus-like particles are able to activate the Ras-MAP kinase pathway and induce cell proliferation. J Virol 75:4150
doi: 10.1128/JVI.75.9.4150-4157.2001 pubmed: 11287564 pmcid: 114160
Fothergill T, McMillan NAJ (2006) Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology 352:319–328. https://doi.org/10.1016/j.virol.2006.05.002
doi: 10.1016/j.virol.2006.05.002 pubmed: 16781758
Schelhaas M, Shah B, Holzer M et al (2012) Entry of human papillomavirus Type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog 8:e1002657. https://doi.org/10.1371/journal.ppat.1002657.t001
doi: 10.1371/journal.ppat.1002657.t001 pubmed: 22536154 pmcid: 3334892
Surviladze Z, Dziduszko A, Ozbun MA (2012) Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus Infections. PLoS Pathog 8:e1002519. https://doi.org/10.1371/journal.ppat.1002519.g007
doi: 10.1371/journal.ppat.1002519.g007 pubmed: 22346752 pmcid: 3276557
Mikuličić S, Finke J, Boukhallouk F et al (2019) ADAM17-dependent signaling is required for oncogenic human papillomavirus entry platform assembly. Elife. https://doi.org/10.7554/eLife.44345
doi: 10.7554/eLife.44345 pubmed: 31107240 pmcid: 6557631
Spoden G, Freitag K, Husmann M et al (2008) Clathrin- and caveolin-independent entry of human papillomavirus type 16–involvement of tetraspanin-enriched microdomains (TEMs). PLoS ONE 3:e3313. https://doi.org/10.1371/journal.pone.0003313
doi: 10.1371/journal.pone.0003313 pubmed: 18836553 pmcid: 2561052
Scheffer KD, Gawlitza A, Spoden GA et al (2013) Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J Virol 87:3435–3446. https://doi.org/10.1128/JVI.02906-12
doi: 10.1128/JVI.02906-12 pubmed: 23302890 pmcid: 3592167
Evander M, Frazer IH, Payne E et al (1997) Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71:2449–2456
doi: 10.1128/jvi.71.3.2449-2456.1997 pubmed: 9032382 pmcid: 191355
Dziduszko A, Ozbun MA (2013) Annexin A2 and S100A10 Regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes. J Virol 87:7502–7515. https://doi.org/10.1128/JVI.00519-13
doi: 10.1128/JVI.00519-13 pubmed: 23637395 pmcid: 3700289
Woodham AW, Da Silva DM, Skeate JG et al (2012) The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS ONE 7:e43519. https://doi.org/10.1371/journal.pone.0043519
doi: 10.1371/journal.pone.0043519 pubmed: 22927980 pmcid: 3425544
Gräßel L, Fast LA, Scheffer KD et al (2016) The CD63-Syntenin-1 complex controls post-endocytic trafficking of oncogenic human papillomaviruses. Sci Rep 6:32337. https://doi.org/10.1038/srep32337
doi: 10.1038/srep32337 pubmed: 27578500 pmcid: 5006017
Fast LA, Mikuličić S, Fritzen A et al (2018) Inhibition of tetraspanin functions impairs human papillomavirus and cytomegalovirus infections. Int J Mol Sci 19:3007. https://doi.org/10.3390/ijms19103007
doi: 10.3390/ijms19103007 pubmed: 30279342 pmcid: 6212908
Hemler ME (2001) Specific tetraspanin functions. J Cell Biol 155:1103–1107. https://doi.org/10.1083/jcb.200108061
doi: 10.1083/jcb.200108061 pubmed: 11756464 pmcid: 2199333
Berditchevski F, Rubinstein E (2013) Tetraspanins. Springer, Berlin
doi: 10.1007/978-94-007-6070-7
Charrin S, Jouannet S, Boucheix C, Rubinstein E (2014) Tetraspanins at a glance. J Cell Sci 127:3641–3648. https://doi.org/10.1242/jcs.154906
doi: 10.1242/jcs.154906 pubmed: 25128561
MacDonald C, Payne JA, Aboian M et al (2015) A family of tetraspans organizes cargo for sorting into multivesicular bodies. Dev Cell 33:328–342. https://doi.org/10.1016/j.devcel.2015.03.007
doi: 10.1016/j.devcel.2015.03.007 pubmed: 25942624 pmcid: 4421094
Florin L, Lang T (2018) Tetraspanin assemblies in virus infection. Front Immunol 9:1140. https://doi.org/10.3389/fimmu.2018.01140
doi: 10.3389/fimmu.2018.01140 pubmed: 29887866 pmcid: 5981178
Hantak MP, Qing E, Earnest JT, Gallagher T (2019) Tetraspanins: architects of viral entry and exit platforms. J Virol 93:674. https://doi.org/10.1128/JVI.01429-17
doi: 10.1128/JVI.01429-17
Hemler ME (2003) Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 19:397–422. https://doi.org/10.1146/annurev.cellbio.19.111301.153609
doi: 10.1146/annurev.cellbio.19.111301.153609 pubmed: 14570575
Yañez-Mó M, Barreiro O, Gordón-Alonso M et al (2009) Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 19:434–446. https://doi.org/10.1016/j.tcb.2009.06.004
doi: 10.1016/j.tcb.2009.06.004 pubmed: 19709882
Reyes R, Cardeñes B, Machado-Pineda Y, Cabañas C (2018) Tetraspanin CD9: a key regulator of cell adhesion in the immune system. Front Immunol 9:863. https://doi.org/10.3389/fimmu.2018.00863
doi: 10.3389/fimmu.2018.00863 pubmed: 29760699 pmcid: 5936783
Charrin S, Le Naour F, Oualid M et al (2001) The major CD9 and CD81 molecular partner. J Biol Chem 276:14329
doi: 10.1074/jbc.M011297200 pubmed: 11278880
Yañez-Mó M, Gutiérrez-López MD, Cabañas C (2011) Functional interplay between tetraspanins and proteases. Cell Mol Life Sci 68:3323–3335. https://doi.org/10.1007/s00018-011-0746-y
doi: 10.1007/s00018-011-0746-y pubmed: 21687991
Gutiérrez-López MD, Gilsanz A, Yañez-Mó M et al (2011) The sheddase activity of ADAM17/TACE is regulated by the tetraspanin CD9. Cell Mol Life Sci 68:3275–3292. https://doi.org/10.1007/s00018-011-0639-0
doi: 10.1007/s00018-011-0639-0 pubmed: 21365281
Tsukamoto S, Takeuchi M, Kawaguchi T et al (2014) Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes. Exp Mol Med 46:e89. https://doi.org/10.1038/emm.2013.161
doi: 10.1038/emm.2013.161 pubmed: 24699135 pmcid: 3944444
Liu J, Zhu G, Jia N et al (2019) CD9 regulates keratinocyte migration by negatively modulating the sheddase activity of ADAM17. Int J Biol Sci 15:493–506. https://doi.org/10.7150/ijbs.29404
doi: 10.7150/ijbs.29404 pubmed: 30745837 pmcid: 6367546
Buck C, Pastrana D, Lowy D, Schiller J (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78:751
doi: 10.1128/JVI.78.2.751-757.2004 pubmed: 14694107 pmcid: 368835
Spoden GA, Besold K, Krauter S et al (2011) Polyethylenimine Is a strong inhibitor of human papillomavirus and cytomegalovirus infection. Antimicrob Agents Chemother 56:75–82. https://doi.org/10.1128/AAC.05147-11
doi: 10.1128/AAC.05147-11 pubmed: 21968369
Bund T, Spoden GA, Koynov K et al (2014) A L2 SUMO Interacting motif is important for PML-localization and infection of human papillomavirus type 16. Cell Microbiol. https://doi.org/10.1111/cmi.12271
doi: 10.1111/cmi.12271 pubmed: 24444361
Snieder B, Brast S, Grabner A et al (2019) Identification of the tetraspanin CD9 as an interaction partner of organic cation transporters 1 and 2. SLAS Discov 24:904–914. https://doi.org/10.1177/2472555219859837
doi: 10.1177/2472555219859837 pubmed: 31318583
Sommer A, Kordowski F, Büch J et al (2016) Phosphatidylserine exposure is required for ADAM17 sheddase function. Nat Commun 7:11523. https://doi.org/10.1038/ncomms11523
doi: 10.1038/ncomms11523 pubmed: 27161080 pmcid: 4866515
Horiuchi K, Le Gall S, Schulte M et al (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18:176–188. https://doi.org/10.1091/mbc.e06-01-0014
doi: 10.1091/mbc.e06-01-0014 pubmed: 17079736 pmcid: 1751309
Knappe M, Bodevin S, Selinka H-C et al (2007) Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem 282:27913–27922. https://doi.org/10.1074/jbc.M705127200
doi: 10.1074/jbc.M705127200 pubmed: 17640876
Rommel O, Dillner J, Fligge C et al (2005) Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J Med Virol 75:114–121. https://doi.org/10.1002/jmv.20245
doi: 10.1002/jmv.20245 pubmed: 15543569
Sapp M, Kraus U, Volpers C et al (1994) Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J Gen Virol 75(Pt 12):3375–3383
doi: 10.1099/0022-1317-75-12-3375 pubmed: 7996132
Le Gall SM, Maretzky T, Issuree PDA et al (2010) ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 123:3913–3922. https://doi.org/10.1242/jcs.069997
doi: 10.1242/jcs.069997 pubmed: 20980382 pmcid: 2972273
Schlöndorff J, Becherer JD, Blobel CP (2000) Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J 347(Pt 1):131–138
doi: 10.1042/bj3470131 pubmed: 10727411 pmcid: 1220940
Taylor JR, Fernandez DJ, Thornton SM et al (2018) Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation. Sci Rep 8:11642. https://doi.org/10.1038/s41598-018-30051-2
doi: 10.1038/s41598-018-30051-2 pubmed: 30076379 pmcid: 6076308
Göoz M (2010) ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45:146–169. https://doi.org/10.3109/10409231003628015
doi: 10.3109/10409231003628015 pubmed: 20184396 pmcid: 2841225
Sahin U, Weskamp G, Kelly K et al (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164:769–779. https://doi.org/10.1083/jcb.200307137
doi: 10.1083/jcb.200307137 pubmed: 14993236 pmcid: 2172154
Gilsanz A, Sánchez-Martín L, Gutiérrez-López MD et al (2013) ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9. Cell Mol Life Sci 70:475–493. https://doi.org/10.1007/s00018-012-1132-0
doi: 10.1007/s00018-012-1132-0 pubmed: 23052204
Wang G-P, Han X-F (2015) CD9 modulates proliferation of human glioblastoma cells via epidermal growth factor receptor signaling. Mol Med Rep 12:1381–1386. https://doi.org/10.3892/mmr.2015.3466
doi: 10.3892/mmr.2015.3466 pubmed: 25760022
Iwasaki T, Takeda Y, Maruyama K et al (2013) Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro. J Biol Chem 288:2118–2131. https://doi.org/10.1074/jbc.M112.424291
doi: 10.1074/jbc.M112.424291 pubmed: 23223239
Taylor JR, Skeate JG, Kast WM (2018) Annexin A2 in virus infection. Front Microbiol. https://doi.org/10.3389/fmicb.2018.02954
doi: 10.3389/fmicb.2018.02954 pubmed: 30700982 pmcid: 6290281
Wüstenhagen E, Hampe L, Boukhallouk F et al (2016) The cytoskeletal adaptor obscurin-like 1 interacts with the human papillomavirus 16 (HPV16) capsid protein L2 and is required for HPV16 endocytosis. J Virol 90:10629–10641. https://doi.org/10.1128/JVI.01222-16
doi: 10.1128/JVI.01222-16 pubmed: 27654294 pmcid: 5110159
Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32:380–387. https://doi.org/10.1016/j.it.2011.05.005
doi: 10.1016/j.it.2011.05.005 pubmed: 21752713
Reiss K, Saftig P (2009) The “a disintegrin and metalloprotease” (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 20:126–137. https://doi.org/10.1016/j.semcdb.2008.11.002
doi: 10.1016/j.semcdb.2008.11.002 pubmed: 19049889
Edwards DR, Handsley MM, Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29:258–289. https://doi.org/10.1016/j.mam.2008.08.001
doi: 10.1016/j.mam.2008.08.001 pubmed: 18762209 pmcid: 7112278
Machado-Pineda Y, Cardeñes B, Reyes R et al (2018) CD9 controls integrin α5β1-mediated cell adhesion by modulating its association with the metalloproteinase ADAM17. Front Immunol 9:2474. https://doi.org/10.3389/fimmu.2018.02474
doi: 10.3389/fimmu.2018.02474 pubmed: 30455686 pmcid: 6230984
Göoz P, Dang Y, Higashiyama S et al (2012) A disintegrin and metalloenzyme (ADAM) 17 activation is regulated by α5β1 integrin in kidney mesangial cells. PLoS ONE 7:e33350. https://doi.org/10.1371/journal.pone.0033350
doi: 10.1371/journal.pone.0033350 pubmed: 22413019 pmcid: 3297637
Grötzinger J, Lorenzen I, Düsterhöft S (2017) Molecular insights into the multilayered regulation of ADAM17: the role of the extracellular region. Biochim Biophys Acta Mol Cell Res 1864:2088–2095. https://doi.org/10.1016/j.bbamcr.2017.05.024
doi: 10.1016/j.bbamcr.2017.05.024 pubmed: 28571693
Berditchevski F (2001) Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 114:4143
doi: 10.1242/jcs.114.23.4143 pubmed: 11739647
Earnest JT, Hantak MP, Park J-E, Gallagher T (2015) Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains. J Virol 89:6093–6104. https://doi.org/10.1128/JVI.00543-15
doi: 10.1128/JVI.00543-15 pubmed: 25833045 pmcid: 4442435
Earnest JT, Hantak MP, Li K et al (2017) The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. PLoS Pathog 13:e1006546. https://doi.org/10.1371/journal.ppat.1006546
doi: 10.1371/journal.ppat.1006546 pubmed: 28759649 pmcid: 5552337
Kummer D, Steinbacher T, Schwietzer MF et al (2020) Tetraspanins: integrating cell surface receptors to functional microdomains in homeostasis and disease. Med Microbiol Immunol 19:638–639. https://doi.org/10.1007/s00430-020-00673-3
doi: 10.1007/s00430-020-00673-3

Auteurs

Snježana Mikuličić (S)

Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Obere Zahlbacher Strasse 67, Augustusplatz, 55131, Mainz, Germany.

Anna Fritzen (A)

Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Obere Zahlbacher Strasse 67, Augustusplatz, 55131, Mainz, Germany.

Konstanze Scheffer (K)

Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Obere Zahlbacher Strasse 67, Augustusplatz, 55131, Mainz, Germany.

Johannes Strunk (J)

Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Obere Zahlbacher Strasse 67, Augustusplatz, 55131, Mainz, Germany.
Max Planck Graduate Center, Mainz, Germany.

Carlos Cabañas (C)

Department of Cell Biology and Immunology, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), 28049, Madrid, Spain.
Department of Immunology, Ophthalmology and Otorhinolaryngology (IOO), Faculty of Medicine, Universidad Complutense, 28040, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), 28041, Madrid, Spain.

Maria Sperrhacke (M)

Department of Dermatology and Allergology, University Hospital Schleswig-Holstein Campus, Rosalind-Franklin-Straße 9, 24105, Kiel, Germany.

Karina Reiss (K)

Department of Dermatology and Allergology, University Hospital Schleswig-Holstein Campus, Rosalind-Franklin-Straße 9, 24105, Kiel, Germany.

Luise Florin (L)

Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Obere Zahlbacher Strasse 67, Augustusplatz, 55131, Mainz, Germany. lflorin@uni-mainz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH